Neuroleptic malignant syndrome and dopaminergic blockade

Area of Science:

• Neuroscience
• Pharmacology
• Toxicology

Background:

• Neuroleptic Malignant Syndrome (NMS) is a rare but life-threatening condition.
• Antipsychotic medications, like haloperidol and chlorpromazine, are known triggers for NMS.
• Dopamine receptor blockade is hypothesized to play a central role in NMS pathogenesis.

Observation:

• A 29-year-old male presented with NMS symptoms including hyperpyrexia, rigidity, autonomic instability, and coma after receiving haloperidol and chlorpromazine.
• The patient subsequently developed rhabdomyolysis, myoglobinuric renal failure, and bilateral anterior tibial compartment syndromes.
• Initial neuroleptic drug levels were within therapeutic ranges, suggesting NMS can occur even without overt toxicity.

Findings:

• Clinical improvement in the patient was observed concurrently with decreasing neuroleptic drug levels.
• Normalization of elevated prolactin levels and increased responsiveness to dopamine hydrochloride infusion were noted.
• These clinical and biochemical changes support a strong association between NMS and dopamine receptor blockade.

Implications:

• This case highlights the critical role of dopamine pathways in the pathophysiology of NMS.
• Understanding the link between dopamine blockade and NMS can inform clinical management and treatment strategies.
• Further research into dopamine receptor sensitivity and NMS is warranted to improve patient outcomes.